TBPH Q4 2018 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+248.5% YoY

Gross Profit

$15M96.0% margin

Operating Income

-$63M-397.9% margin

Net Income

-$50M-318.9% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

+22.6%

Cash Flow

Operating Cash Flow

-$52M

Free Cash Flow

-$54M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$560M

Total Liabilities

$612M

Stockholders' Equity

-$52M

Cash & Equivalents

$378M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$5M	+248.5%
Gross Profit	$15M	$1M	+979.7%
Operating Income	-$63M	-$79M	+20.9%
Net Income	-$50M	-$87M	+42.3%

Revenue Segments

Collaborative Arrangement Revenue

$10M81%

Product

$2M19%